Section Arrow
Quote
VTGN.NASDAQ
- Vistagen Therapeutics, Inc.
(Financial Status)
Quotes are at least 15-min delayed:2026/09/21 23:53 EDT
Regular Hours
Last
 0.233
-0.007 (-2.92%)
Day High 
0.2444 
Prev. Close
0.24 
1-M High
0.269 
Volume 
332.12K 
Bid
0.2307
Ask
0.2456
Day Low
0.2325 
Open
0.236 
1-M Low
0.226 
Market Cap 
10.65M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.24 
20-SMA 0.24 
50-SMA 0.25 
52-W High 5.14 
52-W Low 0.198 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.66/-0.81
Enterprise Value
10.90M
Balance Sheet
Book Value Per Share
0.55
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.27M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.97+0.14+3.66%-- 
MRNAModerna172.94+18.9+12.27%-- 
SLXNSilexion Therapeutics Corp.0.5441+0.1086+24.94%-- 
CELZCreative Medical Technology Holdings1.005+0.0391+4.05%-- 
PDSBPDS Biotechnology Corp0.8419+0.0364+4.52%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mentalfatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.